Eight patents currently held, every record listed here
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Sep 2027. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
4
Ending by 2030
Sep 2027
Next term end
5
Patent families
When these terms end
Each bar runs from grant to computed term end. 2015 to 2038.
US RE47,972
Preparation and Composition of Interalpha Inhibitor Proteins from Human Plasma for Therapeutic Use
Sep 20, 2027
US 10,076,559
Preparation and Composition of Inter-Alpha Inhibitor Proteins from Blood
no later than May 28, 2029
US 12,285,471
Methods for Treating Pulmonary Disease Using Inter-Alpha Inhibitor Proteins
Jun 5, 2038
20202025203020352038
A dotted end marks a recorded terminal disclaimer this site has not resolved: the term can only be shorter than the bar, never longer.
3 pending applications: term is not computable until grant.Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Feb 2030 · High confidence
Also notable
Ends Sep 2027 · Low confidence
Also notable
Ends Sep 2033 · High confidence
Also notable
Ends Jun 2038 · High confidence
Preparation and Composition of Inter-Alpha Proteins from Blood
US 9,139,641
The most cited patent in this portfolio, cited by 20 later US patents, top 25% of utility patents granted in 2015 in our data. Protection runs to 2030.
Preparation and Composition of Interalpha Inhibitor Proteins from Human Plasma for Therapeutic Use
US RE47,972
The largest patent family in this portfolio, 5 related applications, renewed at 3 of 3 maintenance windows. Protection runs to 2027.
Treatment of Disease Using Inter-Alpha Inhibitor Proteins
US 9,572,872
Granted 2017 and renewed at every maintenance window due so far. Protection runs to 2033.
Methods for Treating Pulmonary Disease Using Inter-Alpha Inhibitor Proteins
US 12,285,471
Granted 2025. Too new for citation comparison; protection runs to 2038.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Mar 22, 2027The maintenance fee for Preparation and Composition of Inter-Alpha Proteins from Blood (US 9,139,641) comes due Mar 22, 2027. Unpaid by Sep 22, 2027, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Preparation and Composition of Inter-Alpha Proteins from Blood | 3 in force | to Feb 2030 |
| Treatment of Disease Using Inter-Alpha Inhibitor Proteins | 2 in force | to Sep 2033 |
| Methods for Treating Pulmonary Disease Using Inter-Alpha Inhibitor Proteins | 1 in force | to Jun 2038 |
| Inter-Alpha Inhibitor Proteins | 1 in force | to Apr 2038 |
| Preparation and Composition of Interalpha Inhibitor Proteins from Human Plasma for Therapeutic Use | 1 in force | to Sep 2027 |
Patents held now
Soonest term end first.
Showing 1 to 8 of 8
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US RE47,972 | Preparation and Composition of Interalpha Inhibitor Proteins from Human Plasma for Therapeutic Use In force · Low confidence | In force | Low confidence | |
| US 9,758,570 | Preparation and Composition of Inter-Alpha Inhibitor Proteins from Blood In force · High confidence | In force | High confidence | |
| US 10,076,559 | Preparation and Composition of Inter-Alpha Inhibitor Proteins from Blood In force · Medium confidence | In force | Medium confidence | |
| US 9,139,641 | Preparation and Composition of Inter-Alpha Proteins from Blood In force · High confidence | In force | High confidence | |
| US 9,572,872 | Treatment of Disease Using Inter-Alpha Inhibitor Proteins In force · High confidence | In force | High confidence | |
| US 10,258,675 | Treatment of Disease Using Inter-Alpha Inhibitor Proteins In force · Medium confidence | In force | Medium confidence | |
| US 12,265,090 | Inter-Alpha Inhibitor Proteins In force · High confidence | In force | High confidence | |
| US 12,285,471 | Methods for Treating Pulmonary Disease Using Inter-Alpha Inhibitor Proteins In force · High confidence | In force | High confidence |
Also on record, not counted in the 8: 1 patent ended · 3 applications pending · 8 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.